Observe Medical ASA · OSL:OBSRV
Observe Medical ASA — Q3 2020 Earnings Presentation
32 slides from Observe Medical ASA's earnings presentation, Nov 3, 2020
Slide 1: Observe Medical Q3 2020
OBSERVE MEDICAL Q3 2020 CEO Björn Larsson / CFO Per Arne Nygård Oslo, November 3, 2020
Slide 2: Overview
Overview Sippi® Solid medtech platform for growth Automated and wireless connected digital urine meter for ICUs and wards Strong financial position supported by NOK Strong market opportunity 45 million rights issue in Q3 – accelerated by Covid-19 Current focus: Nordics and Europe
Slide 3: Overview
Overview Sippi® Solid medtech platform for growth Automated and wireless connected digital urine meter for ICUs and wards Strong market opportunity – accelerated by Covid-19 Current focus: Nordics and Europe Enabling accelerated execution of Sippi® commercial Strong financial position supported by
Slide 4: Slide 4
Slide 5: Hourly urine monitoring is the last manual monitoring procedure in the ICU
Hourly urine monitoring of patients is the last remaining manual monitoring procedure in the ICU with significant clinical implications Risk of infections Inaccurate patient data for clinical decisions Time-consuming for staff, reducing clinical capacity
Slide 6: Sippi addresses the clinical challenges
SIPPI® Sippi® addresses the clinical challenges Only automated, digital urine meter with wireless data transfer (Sipplink®) to the hospital patient data management system and which detects (Sippsense®) and hinders (Sippcoat®) bacterial biofilm formation – that can lead to urinary infections. Hinderi
Slide 7: Significant market opportunity for Sippi
SIPPI® Significant market opportunity for Sippi® – outlook remains CURRENT MARKET POTENTIAL ICU CAPABILITIES VOLUME GROWTH SIPPI® SHARE OF MARKET VALUE Sippi® market opportunity ~0.5M +30M +20-30% +100% Sippi® base Sippi® disposable Market volume units units/bags per year Stepwise go-to-market plan
Slide 8: Current focus: Accelerating clinical use in Nordics and selected European markets
SIPPI® Current focus: Accelerating clinical use - in Nordics and selected European markets Examples of impact: NORDICS Infection clinic/ward +30 ENABLER FOR CONTINUED Nya Karolinska hospital, Sweden ACCELERATION: • Sippi® in use, in non-ICU setting • Feedback on clinical use Strengthened access to S
Slide 9: Integration with Sylak immediately strengthens Sippi market access
SYLAK ACQUISITION Integration with Sylak immediately strengthens Sippi® market access Strengthened access to Direct sales Nordics Sippi® target customers Established Nordic sales operations with Competent sales team with team and portfolio relevant to Sippi® established product portfolio target cust
Slide 10: Integration with Sylak immediately strengthens Sippi market access
SYLAK ACQUISITION Integration with Sylak immediately strengthens Sippi® market access Strengthened access to Sippi® target customers Direct sales Nordics Established Nordic sales operations with team and portfolio relevant to Sippi® target customers Distributors Europe Internationally experienced sa
Slide 11: Sylak at a glance
SYLAK ACQUISITION Sylak at a glance Team Internationally experienced sales team, all anaesthesia and intensive care nurses: Sylak AB Anders Nachtweij (General Manager), Swedish medtech company Maria Fogelström (Tender Manager), representing well-established and Klas Eriksson (KAM). suppliers in medt
Slide 12: Financial Review
FINANCIAL REVIEW CFO Per Arne Nygård
Slide 13: Financial review comments
FINANCIAL REVIEW Financial review comments Covid-19 impact • Customer access and relationship-building difficult due to travel restrictions and hospital constraints, thus temporarily slowing down sales processes and delaying revenue growth • The Group has maintained close to full operations during t
Slide 14: Key Figures Profit and Loss Statement
FINANCIAL REVIEW Key Figures Profit and Loss Statement Amounts in NOK thousand The increased Gross result in third (excl. earnings per share) Q3 2020 Q3 2019 YTD 2020 YTD 2019 FY 2019 quarter is due to inventories adjustment in third quarter 2019 Operating revenues 9 22 41 82 177 Increased operating
Slide 15: Statement of Financial Positions Assets
FINANCIAL REVIEW Statement of Financial Positions Assets Amounts in TNOK At 30 September 2020 At 30 September 2019 At 31 December 2019 Goodwill (denominated in SEK) from ASSETS acquisition of Observe Medical Non-current assets International AB in 2015 Goodwill 33 736 29 723 30 333 Intangible assets
Slide 16: Statement of Financial Positions Equity and Liabilities
FINANCIAL REVIEW Statement of Financial Positions Equity and Liabilities Amounts in TNOK At 30 September 2020 At 30 September 2019 At 31 December 2019 Equity as of 30 September at MNOK 40.4 mainly affected by the completed EQUITY AND LIABILITIES rights issue in the quarter deducted the negative resu
Slide 17: Cash Flow Statement third quarter 2020
FINANCIAL REVIEW Cash Flow Statement third quarter 2020 (Amounts in TNOK) 31.430 4 Negative cash flow from operations mainly due to negative result before tax and decreased short term liabilities. Positive cash flow from financing activities mainly due to completed rights issue. As part of the right
Slide 18: Summary and Outlook
SUMMARY AND OUTLOOK CEO Björn Larsson
Slide 19: Summary and outlook
Summary and outlook Summary Outlook +30 Sippi® systems brought to Continued focus on the Nordics clinical use during the last two and Europe months Continuous roll-out of Sippi® Completed acquisition systems for clinical use of Sylak AB – strengthened access to Sippi® target Onboarding Sylak custome
Slide 20: Q&A
Q&A
Slide 21: Thank you!
Thank you!
Slide 22: Finance Calendar
Finance Calendar 20 August 23 February 12 May Presentation of Presentation of Presentation of Q2 and first half Q4 2020 Q1 2021 year 2021 30 April 21 May Publication of Annual General Annual report Meeting 2020
Slide 23: Appendix
Appendix
Slide 24: Management team
OBSERVE MEDICAL AT A GLANCE Experienced management team and board Management team Björn Larsson Per Arne Nygård Mikael Löfgren Kristina Adlesic Chief executive officer Chief financial officer CTO QA/RA MGR Board of directors Terje Bakken Kristin Nyberg Kathrine Gamborg Andreassen Thomas Grünfeld Cha
Slide 25: Condensed Consolidated Statement of Comprehensive Income
(UNAUDITED FOR THE PERIOD ENDED 30 SEPTEMBER 2020) Condensed Consolidated Statement of Comprehensive Income (Amounts in NOK) Q3 2020 Q3 2019 YTD 2020 YTD 2019 FY 2019 Operating revenues 9 112 21 828 41 332 82 261 176 650 Cost of materials 5 203 67 617 126 468 612 350 636 781 Gross result 3 909 -45 7
Slide 26: Condensed Consolidated Statement of Financial Positions
(UNAUDITED FOR THE PERIOD ENDED 30 SEPTEMBER 2020) Condensed Consolidated Statement of Financial Positions (Amounts in NOK) At 30 September 2020 At 30 September 2019 At 31 December 2019 ASSETS Non-current assets Goodwill 33 735 612 29 723 063 30 333 459 Intangible assets 21 669 797 20 891 957 20 997
Slide 27: Condensed Consolidated Statement of Financial Positions
(UNAUDITED FOR THE PERIOD ENDED 30 SEPTEMBER 2020) Condensed Consolidated Statement of Financial Positions (Amounts in NOK) At 30 September 2020 At 30 September 2019 At 31 December 2019 EQUITY AND LIABILITIES Total equity 40 372 000 2 203 484 14 541 734 Non-current liabilities Non-current lease liab
Slide 28: Cash Flow Statement
Cash Flow Statement (UNAUDITED FOR THE PERIOD ENDED 30 SEPTEMBER 2020) (Amounts in NOK) Q3 2020 Q3 2019 YTD 2020 YTD 2019 FY 2019 Cash flow from operating activities Result before tax -5 855 705 -3 917 314 -16 422 739 -12 393 688 -16 917 301 Depreciation and impairment 787 370 1 063 051 2 384 245 3
Slide 29: Top 20 Shareholders – as of October 30, 2020
Top 20 Shareholders – as of October 30, 2020 Rank Name Number of shares % of top 20 % of total Country 1 NAVAMEDIC ASA 4,222,727 25.84% 21.54% NORWAY 2 INGERØ REITEN INV. COMPANY AS 3,939,394 24.10% 20.09% NORWAY 3 RO, LARS 1,450,000 8.87% 7.40% NORWAY 4 UBS SWITZERLAND AG 1,420,522 8.69% 7.25% SWIT
Slide 30: Definitions of Alternative Performance Measures (APM)
Definitions of Alternative Performance Measures (APM) The APMs are regularly reviewed by management and their aim is to enhance stakeholders’ understanding of the company’s performance. APMs presented may be determined or calculated differently by other companies. Gross result: Operating revenues le
Slide 31: Copyright and Disclaimer
Copyright and Disclaimer Copyright Disclaimer expressed or implied, as to the accuracy, Copyright of all published material This Presentation includes and is based, reliability or completeness of the including photographs, drawings and inter alia, on forward-looking information and Presentation, and
Slide 32: Observe Medical
oKeovserve Taaexe |(er=l|